SEMABIZ, Inc.

経口タンパク質およびペプチド市場 – 2029年までの世界予測

MarketsandMarkets  出版レポート一覧

Oral Proteins and Peptides Market – Global Forecast To 2029

経口タンパク質およびペプチド市場 – 分子 (セマグルチド、リナクロチド、カルシトニン)、薬剤クラス (GLP-1 受容体アゴニスト、GEP、CGRP)、治療領域 (糖尿病、消化器病、遺伝性疾患)、製剤 (錠剤、カプセル) – 2029年までの世界予測
Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) – Global Forecast to 2029

The global oral proteins and peptides market is projected to reach USD  20.36  billion by 2029 from USD   7.38  billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029.

世界の経口タンパク質およびペプチド市場は、2024年から2029年の予測期間中に22.5%のCAGRで、2024年の73億8,000万米ドルから2029年までに203億6,000万米ドルに達すると予測されています。

経口タンパク質およびペプチド市場 – 2029年までの世界予測
oral-proteins-peptides-market-Overview

List of  key Companies Profiled in the Report:

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, Advancements in Drug Delivery Technologies, Patient Preference and Compliance for oral route of drug administration, Increasing adoption of inorganic growth strategies such as collaboration and agreement), restraints (High cost is associated with drug development, Contraindication of oral proteins and peptides, Stringent regulatory approval process), opportunities (Robust clinical trial pipeline for oral proteins and peptides drug, Growing demand for non-invasive and patient-friendly treatment options), and Challenges (Hurdles in formulation and stability, Availability of alternative therapies) influencing the growth of the market).
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the oral proteins and peptides market.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.

医療・医薬の最新記事8件